Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Molecular Diagnostics › Thermo Fisher Scientific, Chugai Pharmaceutical Sign Companion Diagnostic Agreement for NSCLC

Thermo Fisher Scientific, Chugai Pharmaceutical Sign Companion Diagnostic Agreement for NSCLC

Jul 08, 2020
|
staff reporter

NEW YORK – Thermo Fisher Scientific said on Wednesday that it has a signed a companion diagnostic agreement with Chugai Pharmaceutical, a member of the Roche group.

In addition, Thermo Fisher has applied to the Ministry of Health, Labor, and Welfare of Japan to expand the use of the Oncomine Dx Target test in that country.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
26
Featured Webinar

CaTCH it if you can! CRISPRa-based Exploration of Therapy Resistant Cell Clones

Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
18
Featured Webinar

Disparities in Precision Oncology: Identifying Barriers and Moving Toward Solutions

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. 

What's Popular?

In Molecular Diagnostics

  1. Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

  2. With Support From Lawmakers, WGS Becoming More Accessible to Netherlands' Cancer Patients

    Premium

  3. Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

  4. Survey of Canadian Cancer Centers Sheds Light on Inequities in Biomarker Test Access

    Premium

  5. AACR Study Tests Immunogenic Signature in Prostate Cancer Patients on Dual Checkpoint Inhibitor

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.